FDA Approvals - Bausch & Lomb Receives FDA Approval Of Besivance(TM), New Topical
Bausch & Lomb Receives FDA Approval Of Besivance(TM), New Topical Ophthalmic Antibacterial For The Treatment Of ... (Medical News Today)
Bausch & Lomb, a world leader in eye health, announced that the U.S. Food and Drug Administration (FDA) approved Besivance(TM) (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis, commonly referred to as "pink eye.
FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System (Medical News Today)
Boston Scientific Corporation (NYSE: BSX) announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.